Following on from information provided to NICE by the company in April 2018, the appraisal of Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
 
Status Discontinued
Technology type Medicine
Decision Selected
Process TA
ID number 1423

Email enquiries

Timeline

Key events during the development of the guidance:

Date Update
10 November 2022 Discontinued. Following on from information provided to NICE by the company in April 2018, the appraisal of Pembrolizumab with epacadostat for untreated malignant melanoma [ID1423] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
11 May 2018 Suspended. Please be advised that the Department for Health and Social Care has asked NICE to carry out a Single Technology Appraisal of pembrolizumab with epacadostat for untreated malignant melanoma. However, the company have advised that the pivotal study did not meet the primary endpoint of improving progression-free survival in the overall population and they will not be seeking regulatory approval from the European Medicines Authority for this indication at this time Therefore, NICE has decided to suspend this appraisal from its work programme. As this appraisal has been referred, NICE will continue to monitor any development and will update interested parties if the situation changes.

For further information on our processes and methods, please see our CHTE processes and methods manual